MannKind (MNKD) Projected to Post Quarterly Earnings on Wednesday

MannKind (NASDAQ:MNKD) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, February 23, 2026 at 4:00 PM ET.

MannKind Price Performance

Shares of MNKD stock opened at $5.54 on Wednesday. The company has a market capitalization of $1.70 billion, a P/E ratio of 55.40 and a beta of 0.84. The company’s 50-day simple moving average is $5.75 and its two-hundred day simple moving average is $5.31. MannKind has a one year low of $3.38 and a one year high of $6.51.

Wall Street Analysts Forecast Growth

MNKD has been the topic of several research analyst reports. Truist Financial set a $9.00 price objective on MannKind in a research note on Monday, November 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of MannKind in a report on Thursday, January 22nd. Leerink Partners assumed coverage on MannKind in a research note on Thursday, November 13th. They set an “outperform” rating and a $7.00 price target on the stock. Royal Bank Of Canada decreased their price objective on MannKind from $8.00 to $7.50 and set an “outperform” rating for the company in a report on Tuesday, November 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of MannKind in a report on Monday, January 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.06.

Insider Buying and Selling

In other MannKind news, CEO Michael Castagna sold 107,920 shares of MannKind stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $5.57, for a total value of $601,114.40. Following the transaction, the chief executive officer directly owned 2,504,792 shares of the company’s stock, valued at approximately $13,951,691.44. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Stuart A. Tross sold 47,006 shares of the company’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $6.33, for a total value of $297,547.98. Following the transaction, the insider directly owned 985,007 shares in the company, valued at approximately $6,235,094.31. The trade was a 4.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 262,846 shares of company stock worth $1,546,840. Insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC increased its position in MannKind by 19.8% during the 1st quarter. AQR Capital Management LLC now owns 55,333 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 9,160 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of MannKind by 3.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 210,565 shares of the biopharmaceutical company’s stock valued at $1,059,000 after acquiring an additional 6,079 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of MannKind by 8.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 670,872 shares of the biopharmaceutical company’s stock valued at $3,374,000 after acquiring an additional 53,202 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of MannKind by 42.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,352,017 shares of the biopharmaceutical company’s stock valued at $5,057,000 after purchasing an additional 404,842 shares during the last quarter. Finally, Prudential Financial Inc. boosted its stake in MannKind by 84.8% in the 2nd quarter. Prudential Financial Inc. now owns 37,381 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 17,150 shares in the last quarter. 49.55% of the stock is currently owned by hedge funds and other institutional investors.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.